

BY EMAIL

Quebec City, April 24, 2018

Ms. Kathryn Nijssen  
Initiatives Manager  
Canadian Clinical Trials Coordinating Centre  
200-119 Ross Avenue,  
Ottawa, ON K1Y 0N6


**Subject : Use of Model Clinical Trial Agreement**

Dear Ms. Nijssen;

Our organization has reviewed the current version of the mCTA and would like to notify CCTCC and our Canadian clinical trial stakeholder community of the following:

1. We will offer and/or accept use of the mCTA for phase II and III industry sponsored clinical trials.
2. We agree to the CCTCC listing our organization as one using the mCTA and the CCTCC maintaining our contact information to facilitate ongoing mCTA initiative communications.
3. We agree to suggest to the CCTCC mCTA changes (if any) on an annual basis and to participate with clinical trial stakeholders in an annual consultation about creation of subsequent mCTA versions.
4. We reserve the right at any time to notify CCTCC if we cease to use the mCTA (Current or subsequent versions) and CCTCC agrees to remove our organization from mCTA user lists.

Sincerely,

  
Serge Rivest, Ph.D.  
CHU de Québec-Université Laval  
2705, boul. Laurier, room T4-44  
Québec QC G1V 4G2  
418 525-4444  
[Serge.Rivest@crchudequebec.ulaval.ca](mailto:Serge.Rivest@crchudequebec.ulaval.ca)